Jazz Pharmaceuticals plc
Dublin, United States · Biopharma, Biotechnology, Health Care
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options. The company's diverse portfolio of transformative medicines extends across the areas of neuroscience, sleep, hematology/oncology, and other therapeutic areas.
Key facts
- Headquarters
- Dublin, United States
- Employees
- 3,430
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (JAZZ)
- Website
- www.jazzpharma.com
- Company page
Recent activity at Jazz Pharmaceuticals plc
- : Jazz Pharmaceuticals Announces Transition in Leadership
- : Jazz Pharmaceuticals acquires Actio Biosciences
- : Jazz Pharmaceuticals and AbCellera Collaborate for Development of Next-Generation T-cell Engaging Antibodies. (date Fundz recorded it)
- : SEC 8-K (5.02): On October 6, 2026, Samantha Pearce, the Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals plc, notified the Company of her intention to retire. Her departure will take effect upon the earlier of her successor's appointment or by June 30, 2027. The Company will initiate a search for her successor, considering internal and external candidates. This leadership change may impact the strategic direction of the company as they prepare for succession.
- : SEC 8-K (1.01): On September 23, 2026, Jazz Pharmaceuticals plc, through its subsidiary Jazz Financing Lux S.à r.l., entered into Amendment No. 4 to the existing Credit Agreement dated May 5, 2021. This amendment is aimed at extending the maturity date and repricing the outstanding U.S. dollar term loan B-2 facility initially incurred on July 19, 2024. Key parties involved include Jazz Lux as the borrower and Bank of America, N.A. serving as the administrative agent. The strategic implications of this amendment are significant as it potentially lowers borrowing costs and provides greater financial flexibility for the company.
- : SEC 8-K (7.01): Jazz Pharmaceuticals plc announced the completion of its acquisition of Actio Biosciences, Inc. on September 15, 2026. Following the acquisition, Actio has become a wholly-owned subsidiary of Jazz Pharmaceuticals. This acquisition marks a strategic expansion for Jazz, potentially enhancing its research and development capabilities. The financial specifics regarding the acquisition amount or terms were not detailed in the announcement. The deal was confirmed through a press release attached as Exhibit 99.1.
- : SEC 8-K (1.01): On August 31, 2026, Jazz Investments I Limited, a wholly-owned subsidiary of Jazz Pharmaceuticals plc, completed a private offering of $1.25 billion in exchangeable senior notes due 2032. This amount includes an additional $150 million exercised by initial purchasers. The estimated net proceeds of approximately $1.226 billion will be used for general corporate purposes, and concurrently, the company repurchased about $225 million of its ordinary shares at $249.29 each. The notes are guaranteed by Jazz Pharmaceuticals and have an interest rate of 1.875%, with semi-annual payments beginning March 15, 2027. This transaction signals a strategic effort to strengthen the company's financial position and share repurchase program.
- : SEC 8-K (8.01): On August 25, 2026, Jazz Pharmaceuticals plc announced via press release that the U.S. Food and Drug Administration approved two regimens containing Ziihera (zanidatamab-hrii) for treating adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The approved regimens are Ziihera plus Tevimbra (tislelizumab-jsgr) and chemotherapy for patients with HER2+ IHC 3+ or IHC 2+/ISH+, as well as Ziihera plus chemotherapy for patients with HER2+ IHC 3+. This significant approval is expected to enhance treatment options and positively impact the company's market position in oncology.
- : SEC 8-K (1.01): On August 10, 2026, Jazz Pharmaceuticals, Inc. entered into a Merger Agreement with Knight Acquisition Corp. to acquire Actio Biosciences, Inc. for an Aggregate Upfront Transaction Value of $820 million. This acquisition will occur through a merger where Actio will become a wholly-owned subsidiary of Jazz. The per-share consideration for Actio's capital stock will be determined by the Aggregate Upfront Transaction Value divided by the fully diluted number of shares, with provisions for adjustments based on the Company's financial status. Additionally, the agreement includes potential contingent milestone payments of up to $500 million related to future developments, which highlights the strategic importance of this acquisition for Jazz's growth and pipeline enhancement.
- : SEC 8-K (7.01): On August 10, 2026, Jazz Pharmaceuticals Public Limited Company and Actio Biosciences, Inc. issued a joint press release regarding an important update in their operations. The press release contains information that could impact investors and stakeholders and is therefore being disclosed under Regulation FD. This filing demonstrates the companies' commitment to transparency and provides necessary information to the public and investors following securities laws. The specific details of what was disclosed in the press release are included in the attached Exhibit 99.1.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Samantha Pearce, Chief Commercial Officer
- Renee Gala, President
- Sam Pearce, Chief Commercial Officer
- Philip Johnson, Chief Financial Officer
Verified email and direct lines for Jazz Pharmaceuticals plc’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Jazz Pharmaceuticals plc files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Jazz Pharmaceuticals plc in the news
Companies similar to Jazz Pharmaceuticals plc
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- MacroGenics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Bristol Myers Squibb · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- AbbVie Inc. · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
About Jazz Pharmaceuticals plc: questions and answers
What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options. The company's diverse portfolio of transformative medicines extends across the areas of neuroscience, sleep, hematology/oncology, and other therapeutic areas.
Where is Jazz Pharmaceuticals plc headquartered?
Jazz Pharmaceuticals plc is headquartered in Dublin, United States.
How many employees does Jazz Pharmaceuticals plc have?
Jazz Pharmaceuticals plc has about 3,430 employees.
Who leads Jazz Pharmaceuticals plc?
Renee Gala is a President at Jazz Pharmaceuticals plc.
What is the latest news on Jazz Pharmaceuticals plc?
On Oct 9, 2026, Jazz Pharmaceuticals Announces Transition in Leadership
Is Jazz Pharmaceuticals plc a public company?
Yes. Jazz Pharmaceuticals plc is publicly traded under the ticker JAZZ.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy